Waldencast plc - Class A Ordinary Share (NQ:WALD)

1.110 -0.110 (-9.02%)

Streaming Delayed Price Updated: 2:59 PM EDT, Mar 24, 2026 Add to My Watchlist

Price and Volume

Volume	64,625
Open	1.210
Bid (Size)	1.100 (1,200)
Ask (Size)	1.120 (200)
Prev. Close	1.220
Today's Range	1.100 - 1.220
52wk Range	1.170 - 3.340
Shares Outstanding	9,342,874
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Obagi Medical Introduces NU-GEN™ Cellular Renewal Serum Designed to Visibly Rewind Skin’s Age and Restore Visible Youthfulness

Today 8:35 EDT

The clinically proven formula pairs NAD+ with its precursors to replenish skin cells and address nine signs of skin aging for healthier, more resilient-looking skin

From Waldencast plc

Via GlobeNewswire

Obagi Medical and ProMD Announce Collaboration in the ALOHA Program to Advance Clinical Evidence with Obagi® saypha® MagIQ™

March 19, 2026

ProMD’s multi-location physician led network will participate in Obagi’s ALOHA Program as part of a structured evaluation of MagIQ and integrated skincare protocols to providers across multiple states

From Waldencast plc

Via GlobeNewswire

Performance

YTD	-35.1%	-35.1%
1 Month	-35.5%	-35.5%
3 Month	-42.2%	-42.2%
6 Month	-46.5%	-46.5%
1 Year	-64.8%	-64.8%

More News

Waldencast Reports Q4 2025 and FY 2025 Financial Results

March 13, 2026

From Waldencast plc

Via GlobeNewswire

Waldencast plc Announces Fourth Quarter and Fiscal Year 2025 Earnings Date

March 11, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical and Schweiger Dermatology Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

February 27, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical and It’s a Secret Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

February 25, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical and Aesthetic Record Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

February 17, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical and DermFx Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

February 06, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical and Moxie Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

February 05, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical Introduces New Lip Therapy Protocol Designed to Resurface, Replenish, and Protect

February 03, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical and VIO Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

January 30, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical and Next Health Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

January 28, 2026

From Waldencast plc

Via GlobeNewswire

UPDATE - Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ™

January 27, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ™

January 27, 2026

From Waldencast plc

Via GlobeNewswire

CORRECTION – Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

January 26, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

January 26, 2026

From Waldencast plc

Via GlobeNewswire

Obagi Medical Unveils ALOHA Program to Launch Obagi® saypha® MagIQ™ – Pioneering the Largest Real-World Evaluation of a New Hyaluronic Acid Filler

January 21, 2026

From Waldencast plc

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD

January 06, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD

December 30, 2025

From Pomerantz LLP

Via GlobeNewswire

Waldencast Announces Q2 2025 Results and Provides Q3 2025 Trading Update

November 24, 2025

From Waldencast plc

Via GlobeNewswire

Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting

November 16, 2025

From Waldencast plc

Via GlobeNewswire

Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilities

November 14, 2025

From Waldencast plc

Via GlobeNewswire

Waldencast plc Provides Information Regarding Upcoming Earnings Release Dates

November 12, 2025

From Waldencast plc

Via GlobeNewswire

Obagi Medical Launches Nu-Cil® BioStim™ Scalp Serum

October 08, 2025

From Waldencast plc

Via GlobeNewswire

Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand

September 10, 2025

From Waldencast plc

Via GlobeNewswire

Frequently Asked Questions

Is Waldencast plc - Class A Ordinary Share publicly traded?

Yes, Waldencast plc - Class A Ordinary Share is publicly traded.

What exchange does Waldencast plc - Class A Ordinary Share trade on?

Waldencast plc - Class A Ordinary Share trades on the Nasdaq Stock Market

What is the ticker symbol for Waldencast plc - Class A Ordinary Share?

The ticker symbol for Waldencast plc - Class A Ordinary Share is WALD on the Nasdaq Stock Market

What is the current price of Waldencast plc - Class A Ordinary Share?

The current price of Waldencast plc - Class A Ordinary Share is 1.110

When was Waldencast plc - Class A Ordinary Share last traded?

The last trade of Waldencast plc - Class A Ordinary Share was at 03/24/26 02:59 PM ET

What is the market capitalization of Waldencast plc - Class A Ordinary Share?

The market capitalization of Waldencast plc - Class A Ordinary Share is 10.37M

How many shares of Waldencast plc - Class A Ordinary Share are outstanding?

Waldencast plc - Class A Ordinary Share has 10M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.